Patients undergoing bone marrow transplantation are highly immunocompromised and vulnerable to invasive bacterial, fungal, and mycobacterial infection. Immunocompromise in this patient population is multifactorial and depends on the type of transplant and the immunosuppressive regimen that has been given to prevent graft-versus-host disease. Furthermore, the nature of immunocompromise changes as bone marrow engrafts and various cell populations return and become functional. We have established a prospective database for surveillance of infections in these patients. The database provides a valuable resource for patient care as well as for correlation studies. Currently we are focusing on the broader impact (including morbidity and quality of life) of dsDNA viruses (herpes viruses, adenovirus, and BK polyoma virus) on the outcomes of transplantation. We are also evaluating the impact of therapeutic interventions targeted to these viruses.
Infection is one of the main causes of death after bone marrow transplantation. Our goal is to reduce infection-related mortality by 1) defining clinical factors or biomarkers for specific infections and outcomes; 2) identifying highly susceptible groups of patients that may benefit from prophylaxis or intensive monitoring; 3) assessing the utility of novel diagnostic or therapeutic interventions.
Translational and Clinical Research
Preferred Project Dates
- June 15 – August 7
- June 22 – August 14